In contrast to our prediction that CARM1 would be highly expressed in steroid receptor-rich tumors, CARM1 was only overexpressed in a small fraction of these tumors (27% of breast tumors, 6% of prostate cancers, and 17% of ovarian cancers). Here, CARM1 is linked to prostate cancer.